PulseAugur
中
实时 17:40:57

Insilico Medicine advances AI-discovered drug rentosertib to Phase III trials for IPF

作者 PulseAugur 编辑部 · [2 个来源] ·

Insilico Medicine is moving its AI-discovered drug, rentosertib, into Phase III clinical trials for idiopathic pulmonary fibrosis (IPF). The drug, which targets the TNIK protein, showed promising results in Phase II trials with a significant improvement in lung function for patients receiving a 60 mg daily dose. This advancement highlights the potential of AI in accelerating drug discovery and development, reducing the time from project initiation to preclinical candidate nomination to 18 months. AI

影响 Accelerates the validation of AI-discovered therapeutics, potentially reducing drug development timelines and costs.

排序理由 The cluster reports on a drug identified and designed by AI that has reached Phase III clinical trials, a significant milestone in AI-driven drug discovery.

在 Artificial Intelligence News 阅读 →

AI 生成摘要 · Google Gemini · 来自 2 个来源。 我们如何撰写摘要 →

Insilico Medicine advances AI-discovered drug rentosertib to Phase III trials for IPF

本文如何被排名

Signal score
0 / 100
Composite score across the factors below. Higher = stronger signal that this story matters right now.
Newsworthiness bucket
Research
The cluster reports on a drug identified and designed by AI that has reached Phase III clinical trials, a significant milestone in AI-driven drug discovery.
Source corroboration
2 independent sources
Multiple independent publishers reporting the same story raises confidence that it's real and newsworthy.
Topics
model release, product
Editorial topic classification. Feeds into how the story surfaces on /topic/<slug> hub pages and into the per-entity coverage mix.
AI-industry relevance
High
Clearly on-topic for AI-industry coverage.
Story freshness
93 days old
Aged out of breaking-news scoring windows; ranking reflects the durable signal from the full source set.

完整方法见我们的编辑标准。

报道来源 [2]

  1. Artificial Intelligence News TIER_1 English(EN) · Ryan Daws ·

    Insilico Medicine 将其 AI 药物 IPF 推向 III 期试验

    <p>Insilico Medicine is advancing to Phase III human trials for testing a drug identified by AI targeting idiopathic pulmonary fibrosis (IPF). This progression supplies the computational drug discovery sector with empirical test cases, advancing an AI medicine past early safety e…

  2. Mastodon — mastodon.social TIER_1 English(EN) · [email protected] ·

    Insilico Medicine将AI发现并由生成式AI设计的口服抑制剂rentosertib推进至III期人体临床试验。https://www.artif

    Insilico Medicine has advanced rentosertib, an AI-discovered and generative-AI-designed oral inhibitor, into Phase III human clinical trials. https://www. artificialintelligence-news.co m/news/insilico-medicine-advances-ai-drug-for-ipf-to-phase-iii-trials/ # ai # medicine # healt…

相关实体

相关话题